Cell-based immunotherapy uses components of the immune system to mount a powerful fight against cancer. In our lab, we leverage natural killer cells, alongside other cells of the immune system, as powerful tools for the treatment of malignant diseases. We combine approaches in cell therapy, gene engineering and nanomedicine to develop translational new therapeutic solutions.
Operating at the nanoscale affords size- and structure- related behaviors that differ significantly from those of bulk materials and which can have significant therapeutic advantage. To evolve nanotherapeutics as efficient drug substances, we are studying and developing polymeric and liposomal nanoparticles to improve their biological function, targeting ability and therapeutic efficacy.
One of the critical elements for the clinical availability of cells for use in immunotherapy is cryopreservation. However, cryopreserving cells largely relies on antiquated protocols which raise serious safety concerns. In our lab, we are developing new approaches that marry novel biomaterials with cellular biophysics to develop next-generation primary cell cryopreservation approaches.